XENE

40.57

1.45% 0.58

Handel nachbörslich: 40.57

Xenon Pharmaceuticals Inc (XENE)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$39.99

Offen:

$39.82

24-Stunden-Volumen:

432.43K

Relative Volume:

0.53

Marktkapitalisierung:

$3.13B

Einnahmen:

$13.17M

Nettoeinkommen (Verlust:

$-199.06M

KGV:

-14.81

EPS:

-2.74

Netto-Cashflow:

$-156.53M

1W Leistung:

+3.60%

1M Leistung:

+12.04%

6M Leistung:

+21.32%

1J Leistung:

-2.85%

1-Tages-Spanne:

$39.41

$40.92

1-Wochen-Bereich:

$38.98

$41.66

52-Wochen-Spanne:

$26.74

$46.00

Xenon Pharmaceuticals Inc Stock (XENE) Company Profile

Firmenname

Xenon Pharmaceuticals Inc

Sektor

Healthcare (1140)

Branche

Biotechnology (636)

Telefon

(604) 484-3300

Adresse

200 - 3650 GILMORE WAY, BURNABY

Mitarbeiter

327

Twitter

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

XENE's Discussions on Twitter

Vergleichen Sie XENE mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
XENE Xenon Pharmaceuticals Inc	40.57	3.08B	13.17M	-199.06M	-156.53M	-2.74
VRTX Vertex Pharmaceuticals Inc	412.22	104.45B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	469.36	60.95B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	572.60	59.11B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	812.95	49.23B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	320.94	35.92B	4.56B	-176.77M	225.30M	-1.7177

Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-09-03	Fortgesetzt	Wells Fargo	Overweight
2025-05-07	Eingeleitet	Chardan Capital Markets	Buy
2025-02-11	Eingeleitet	Deutsche Bank	Buy
2024-10-10	Fortgesetzt	Raymond James	Outperform
2024-10-01	Eingeleitet	H.C. Wainwright	Buy
2024-01-04	Eingeleitet	Citigroup	Buy
2023-12-08	Eingeleitet	Robert W. Baird	Outperform
2023-10-24	Fortgesetzt	Cantor Fitzgerald	Overweight
2023-04-25	Eingeleitet	Cantor Fitzgerald	Overweight
2022-12-14	Eingeleitet	Goldman	Buy
2022-12-12	Eingeleitet	Cowen	Outperform
2022-11-28	Eingeleitet	Wells Fargo	Overweight
2022-10-19	Eingeleitet	Raymond James	Outperform
2022-08-29	Eingeleitet	BofA Securities	Buy
2022-07-21	Eingeleitet	JP Morgan	Overweight
2021-10-28	Eingeleitet	RBC Capital Mkts	Outperform
2020-10-02	Eingeleitet	SVB Leerink	Outperform
2020-07-21	Eingeleitet	Needham	Buy
2020-06-01	Fortgesetzt	Jefferies	Buy
2020-03-25	Eingeleitet	Wedbush	Outperform
2020-01-08	Eingeleitet	William Blair	Outperform
2019-09-20	Eingeleitet	Guggenheim	Buy
2018-08-08	Bestätigt	Stifel	Buy
2017-03-13	Eingeleitet	Jefferies	Buy
2016-10-21	Eingeleitet	Stifel	Buy
2016-09-26	Eingeleitet	Guggenheim	Buy
2016-04-14	Bestätigt	Jefferies	Buy
2015-10-30	Fortgesetzt	Jefferies	Buy
2014-12-02	Eingeleitet	Canaccord Genuity	Buy

Alle ansehen

Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten

07:23 AM

Xenon Pharmaceuticals Inc.’s volatility index tracking explained2025 AllTime Highs & Low Drawdown Investment Ideas - newser.com

07:23 AM

06:27 AM

Will Xenon Pharmaceuticals Inc. stock maintain growth storyPortfolio Return Report & Technical Confirmation Trade Alerts - newser.com

06:27 AM

12:28 PM

Will Xenon Pharmaceuticals Inc. price bounce be sustainableWeekly Market Report & Advanced Swing Trade Entry Plans - newser.com

12:28 PM

Oct 13, 2025

Why Xenon Pharmaceuticals Inc. stock is trending among retail tradersJuly 2025 Trade Ideas & Free Real-Time Market Sentiment Alerts - newser.com

Oct 13, 2025

Published on: 2025-10-13 08:53:34 - newser.com

Oct 13, 2025

Mirae Asset Global Investments Co. Ltd. Purchases 403 Shares of Xenon Pharmaceuticals Inc. $XENE - Defense World

Oct 13, 2025

Oct 12, 2025

Will Xenon Pharmaceuticals Inc. stock attract more institutional investorsWeekly Trade Recap & Entry Point Confirmation Alerts - newser.com

Oct 12, 2025

Xenon Pharmaceuticals (XENE): Exploring Valuation After Recent Share Price Momentum - Yahoo Finance

Oct 12, 2025

Oct 11, 2025

Leerink Partners Remains a Buy on Xenon (XENE) - The Globe and Mail

Oct 11, 2025

Evaluating Xenon Pharmaceuticals (XENE): Is the Current Valuation Justified After Recent Share Price Momentum? - Sahm

Oct 11, 2025

Oct 10, 2025

Will Xenon Pharmaceuticals Inc. stock attract ESG investorsDay Trade & Free Weekly Watchlist of Top Performers - newser.com

Oct 09, 2025

Is Xenon Pharmaceuticals Inc. stock attractive for income investors2025 Trading Recap & Capital Efficiency Focused Ideas - newser.com

Oct 09, 2025

Is Xenon Pharmaceuticals a Smart Investment After Its New Clinical Trial Partnership? - Sahm

Oct 09, 2025

Oct 08, 2025

What analysts say about Xenon Pharmaceuticals Inc stockInsider Selling Patterns & Budget Friendly Trading Strategies - earlytimes.in

Oct 08, 2025

Brokers Offer Predictions for XENE FY2026 Earnings - MarketBeat

Oct 08, 2025

Bloom Burton Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to "Strong-Buy" - MarketBeat

Oct 08, 2025

Xenon Pharmaceuticals’ (XENE) Outperform Rating Reaffirmed at William Blair - Defense World

Oct 08, 2025

Xenon Pharmaceuticals (NASDAQ:XENE) Given “Buy” Rating at Chardan Capital - Defense World

Oct 08, 2025

Oct 07, 2025

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Oct 07, 2025

77,750 Options: Xenon Pharmaceuticals Grants Equity to Seven New Hires at $39.20, Oct 2, 2025 - Stock Titan

Oct 07, 2025

Xenon Pharmaceuticals' (XENE) Outperform Rating Reiterated at William Blair - MarketBeat

Oct 07, 2025

Xenon Pharmaceuticals (NASDAQ:XENE) Receives "Buy" Rating from Chardan Capital - MarketBeat

Oct 07, 2025

XENE: Chardan Capital Maintains Buy Rating with $55 Price Target - GuruFocus

Oct 07, 2025

Chardan Capital Maintains Xenon Pharmaceuticals (XENE) Buy Recommendation - Nasdaq

Oct 07, 2025